Company: APXIF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026189
Chunk: 274

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 274
---
mation of the Business Combination, there can be no guarantee that Nasdaq will approve such
initial listing application, which may delay, or ultimately prevent the consummation of the proposed Business Combination.

If we are unable to consummate the Business Combination
or any other business combination and are forced to liquidate, our investors would not be able to realize the benefits of owning shares
in a successor operating business, including the potential appreciation in the value of our securities following such a transaction,
and any Public Warrants held by our investors would expire worthless.

Holders of our public shares will not be entitled to vote on
the appointment of directors prior to our initial business combination. 

Prior to our initial business combination, only
holders of Class B ordinary shares will have the right to appointment directors in any general meeting. Holders of our public shares
will not be entitled to vote on the appointment of directors during such time. Accordingly, you may not have any say in the management
of our company prior to the completion of an initial business combination.

If we seek shareholder approval of our initial business combination
and we do not conduct redemptions pursuant to the tender offer rules, and if you or a “group” of shareholders are deemed
to hold in excess of 15% of our Class A ordinary shares, you will lose the ability to redeem all such shares in excess of 15% of our
Class A ordinary shares. 

If we seek shareholder approval of our initial
business combination and we do not conduct redemptions in connection with our initial business combination pursuant to the tender offer
rules, our Articles provide that a public shareholder, together with any affiliate of such shareholder or any other person with whom
such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Exchange Act), will be restricted
from seeking redemption rights with respect to more than an aggregate of 15% of the shares sold in the IPO without our prior consent,
which we refer to as the “Excess Shares.” However, we would not be restricting our shareholders’ ability to vote all
of their shares (including Excess Shares) for or against our initial business combination. Your inability to redeem the Excess Shares
will reduce your influence over our ability to complete our initial business combination and you could suffer a material loss on your
investment in us if you sell Excess Shares in open market transactions. Additionally, you will not receive redemption distributions with
respect to the Excess Shares if we complete our initial business